Lexicon Pharmaceuticals | LXRX - Ebitda


Lexicon Pharmaceuticals reported $-12.04M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 9.46B 3.54B Sep/2026
Halozyme Therapeutics USD 336.16M 7.34M Sep/2026
Illumina USD 330M 80M Jun/2026
Insmed USD -80.97M 93.7M Sep/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
J&J USD 8.99B 721M Jun/2026
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
MacroGenics USD -64.54M 34.34M Jun/2026
MannKind USD 2.47M 461K Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Moderna USD -687M 571M Jun/2026
Novartis USD 8.62B 2.14B Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Thermo Fisher Scientific USD 3.79B 244M Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
United Therapeutics USD 334.2M 20.8M Sep/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024